首页> 外文期刊>European journal of preventive cardiology >Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment
【24h】

Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment

机译:高敏C反应蛋白在接受最佳药物治疗的急性冠脉综合征患者中的预后价值

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: High-sensitivity C-reactive protein (hsCRP) has been reported to have a prognostic value immediately after acute coronary syndrome (ACS) and to be associated with the onset of cardiovascular (CV) events in patients with stable and unstable angina pectoris. Aim: To evaluate whether or not hsCRP levels can be used to predict future CV events in a prospective study of post-ACS patients receiving an optimized medical treatment (OMT) secondary-prevention regimen.Methods: OMT along with therapeutic and dietary education programmes were started during the acute phase, then monitored and adjusted as needed at 3 months post ACS. hsCRP was measured at 3 months after the ACS, and a global evaluation of atherosclerosis burden and risk factors were also evaluated at this time point. The study population was divided into tertiles based on their hsCRP value and followed for CV events. Results: A total of 1202 consecutive patients with hsCRP <15 mg/l were included in the study, 795 of which were followed for an average of 22 months. LDL-cholesterol, HbA1c, waist circumference, systolic blood pressure, metabolic syndrome, tobacco consumption, and atherosclerosis burden were higher in patients in the second and third tertile of hsCRP (p < 0.001) than those in the first tertile, at 3 months. hsCRP level was not found to be associated with recurrence of total CV events (HR 1.29, CI 0.83-2.00) in univariate analysis. We further examined the effect of adding hsCRP levels to the Framingham risk evaluation score, and found no significant improvement the C-statistics of the Framingham risk evaluation score. Conclusion: hsCRP is associated with CV risk factors, but is not an independent predictor of future events in post-ACS patients receiving an OMT secondary-prevention regimen. ? 2011 The European Society of Cardiology.
机译:背景:据报道,高敏C反应蛋白(hsCRP)在急性冠状动脉综合征(ACS)后立即具有预后价值,并且与稳定和不稳定型心绞痛患者的心血管事件(CV)发作有关。目的:在接受优化药物治疗(OMT)二级预防方案的ACS后患者的前瞻性研究中,评估hsCRP水平是否可用于预测未来的心血管事件。方法:OMT以及治疗和饮食教育计划开始于急性期,然后在ACS后3个月根据需要进行监测和调整。在ACS后3个月测量hsCRP,并在此时评估动脉粥样硬化负担和危险因素的整体评估。根据研究对象的hsCRP值将其分为三分位数,然后进行CV事件追踪。结果:本研究共纳入1202例hsCRP <15 mg / l的连续患者,其中795例平均随访22个月。在3个月时,hsCRP第二和第三三分位数患者的LDL-胆固醇,HbA1c,腰围,收缩压,代谢综合征,烟草消耗和动脉粥样硬化负担均高于第一三分位数的患者(p <0.001)。在单变量分析中,未发现hsCRP水平与总CV事件的复发(HR 1.29,CI 0.83-2.00)相关。我们进一步检查了将hsCRP水平添加到Framingham风险评估评分中的效果,发现Framingham风险评估评分的C统计量没有显着改善。结论:hsCRP与CV危险因素有关,但不是接受OMT二级预防方案的ACS后患者未来事件的独立预测因子。 ? 2011年,欧洲心脏病学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号